CONFIDENTIAL — APPROVED FOR PUBLIC RELEASE · BUREAU FILE COPY RECORDS CURRENT AS OF 29 MAY 2026 · DISTRIBUTION: UNRESTRICTED
VendorInvestigator Independent Testing Bureau · Public Records Division
DOCKET YEAR 2026 · VOL. II
35,156 SAMPLES ON FILE
No fee · No favor
Compound Evidence File
#EC-2026-0053

Tadalafil Raw

Filed under Raw Materials. The bureau holds 130 laboratory returns for this compound from 43 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.

Cross-Index

Subjects Shipping This Compound

43 SUBJECTS
SubjectGradeSamplesMeanMinMaxFirst seenLast seen
WuXi TIDESCASE #VI-2026-0335 A 5 10.0 9.9 10.0 23 Nov 2025 24 May 2026
Kerui PeptidesCASE #VI-2026-0626 A 4 10.0 9.9 10.0 2 Jun 2026 12 Jul 2026
Hubei JianxiangCASE #VI-2026-0048 A 4 10.0 9.9 10.0 27 Dec 2025 16 Jun 2026
Shanghai Sigma AudleyCASE #VI-2026-0505 A 4 10.0 9.9 10.0 21 Jan 2026 7 Jul 2026
Thermo Fisher ScientificCASE #VI-2026-0142 A 4 10.0 9.9 10.0 6 Apr 2026 27 Jul 2026
SinoPepCASE #VI-2026-0387 A 4 10.0 9.9 10.0 5 Jul 2026 13 Aug 2026
Sangon BioCASE #VI-2026-0671 A 3 10.0 9.9 10.0 28 Feb 2026 24 May 2026
Chinese Peptide CompanyCASE #VI-2026-0184 A 3 10.0 9.9 10.0 28 Feb 2026 27 Apr 2026
GenScript PeptidesCASE #VI-2026-0860 A 3 10.0 9.9 10.0 9 May 2026 4 Aug 2026
PolyPeptide GroupCASE #VI-2026-0143 A 3 10.0 9.9 10.0 8 Feb 2026 18 Aug 2026
QYAOBIOCASE #VI-2026-0861 A 2 10.0 10.0 10.0 18 May 2026 9 Jun 2026
Mokemei BiotechnologyCASE #VI-2026-0540 A 2 10.0 10.0 10.0 3 May 2026 14 Jun 2026
Shanghai Wibson BiotechnologyCASE #VI-2026-0379 A 2 10.0 10.0 10.0 1 Jan 2026 2 Mar 2026
Hybio PharmaceuticalCASE #VI-2026-0065 A 2 10.0 10.0 10.0 8 Apr 2026 23 Jun 2026
HomopeptideCASE #VI-2026-0760 A 6 9.9 9.9 9.9 24 May 2026 24 May 2026
Tianjin Finder Chemical TFCCASE #VI-2026-0693 A 6 9.9 9.9 10.0 14 Nov 2025 16 Apr 2026
JEEP PeptidesCASE #VI-2026-0457 A 4 9.9 9.9 10.0 5 Feb 2026 1 Jul 2026
Flourishglobal PeptideCASE #VI-2026-0630 A 4 9.9 9.9 10.0 1 Feb 2026 12 Jul 2026
AmbioPharmCASE #VI-2026-0177 A 4 9.9 9.9 10.0 11 Jul 2026 20 Aug 2026
BachemCASE #VI-2026-0314 A 3 9.9 9.9 9.9 17 Dec 2025 8 Jun 2026
AsymchemCASE #VI-2026-0091 A 3 9.9 9.9 10.0 6 Jul 2026 7 Aug 2026
Shanghai ERP BiotechnologyCASE #VI-2026-0936 A 2 9.9 9.9 10.0 16 Apr 2026 3 Jun 2026
Sigma-AldrichCASE #VI-2026-0829 A 2 9.9 9.9 9.9 22 Feb 2026 13 Jun 2026
NUPEPS PeptidesCASE #VI-2026-0896 X 1 9.7 9.7 9.7 24 Apr 2025 24 Apr 2025
Qingdao Sigma Chemical QSCCASE #VI-2026-0538 A 7 8.7 7.7 9.8 23 May 2026 23 May 2026
Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 A 6 8.5 7.2 10.0 23 May 2026 23 May 2026
Glbiochem (Shanghai)CASE #VI-2026-0704 A 4 8.5 7.9 8.9 24 May 2026 24 May 2026
Pura PeptidesCASE #VI-2026-0307 X 1 8.5 8.5 8.5 27 Feb 2025 27 Feb 2025
Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 A 4 8.3 7.0 9.4 21 May 2026 21 May 2026
Shanghai Sigma Audley SSACASE #VI-2026-0486 A 3 8.3 7.4 9.0 21 May 2026 21 May 2026
Peptide PartnersCASE #VI-2026-0295 X 1 8.3 8.3 8.3 28 Mar 2025 28 Mar 2025
LN PeptidesCASE #VI-2026-0781 X 1 8.0 8.0 8.0 20 Jun 2025 20 Jun 2025
Kits4lessCASE #VI-2026-0744 X 1 7.6 7.6 7.6 14 Jan 2025 14 Jan 2025
BfflinkCASE #VI-2026-0212 X 1 7.0 7.0 7.0 16 Mar 2025 16 Mar 2025
Evolve BioPepCASE #VI-2026-0755 X 1 6.9 6.9 6.9 6 May 2025 6 May 2025
Changan District Sheng Peptide TradingCASE #VI-2026-0341 X 1 6.9 6.9 6.9 21 May 2025 21 May 2025
Peptide SciencesCASE #VI-2026-0867 X 6 6.7 5.3 7.8 3 Jul 2025 24 May 2026
Allen Biotechnology Co ABCCASE #VI-2026-0709 X 4 6.5 5.3 7.3 3 Jul 2025 23 May 2026
NextechLabsCASE #VI-2026-0285 X 2 6.5 6.4 6.6 3 Jul 2025 19 Jan 2026
Xingtai Jiachuang TechnologyCASE #VI-2026-0712 X 1 6.3 6.3 6.3 16 Mar 2025 16 Mar 2025
TSC Top Supplements ChinaCASE #VI-2026-0523 X 3 6.1 4.6 7.2 14 Jan 2025 24 May 2026
Platinum CryoCASE #VI-2026-0406 X 2 5.0 4.4 5.5 13 Jun 2025 17 May 2026
Advanced Technology and IndustrialCASE #VI-2026-0133 X 1 0.0 0.0 0.0 3 Jul 2025 3 Jul 2025

Open any subject to view the batch-level evidence for Tadalafil Raw alone.